TIPARP — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL8221645	0.65	19/20
SCHEMBL2120603	0.47	13/20
SCHEMBL2617834	0.47	13/20
SCHEMBL2120737	0.43	12/20
SCHEMBL2617817	0.43	12/20
SCHEMBL2617885	0.43	12/20
SCHEMBL2119362	0.45	11/20
SCHEMBL2617784	0.45	11/20
SCHEMBL2617850	0.45	11/20
SCHEMBL13012676	0.49	10/20
SCHEMBL13012375	0.47	9/20
SCHEMBL11916248	0.61	6/20
SCHEMBL11945587	0.49	6/20
SCHEMBL11946229	0.47	5/20
SCHEMBL1025208	0.47	5/20
SCHEMBL12408518	0.40	5/20
SCHEMBL3531100	0.40	5/20
SCHEMBL2120741	0.39	5/20
SCHEMBL3535475	0.33	5/20
SCHEMBL2226665	0.51	4/20

Clinical trials — most relevant to TIPARP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)	PHASE1/PHASE2	RECRUITING
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)	PHASE2	RECRUITING
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib	PHASE2	COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
Nucleoside Therapy in Patients With Telomere Biology Disorders	PHASE1	RECRUITING
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Project SIRT6 Activator	nan	RECRUITING
Sirtuin1 in COVID19 Patients	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart	nan	UNKNOWN
Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects	nan	WITHDRAWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
How Sirtuin Levels Change During Behçet Disease	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Stress and Treatment Response in Puerto Rican Children With Asthma	nan	COMPLETED
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TIPARP binder may also engage these)

Protein	Name	Similarity
Q8C1B2	—	1.000	Q8C1B2 →
D2H3M0	—	0.982	D2H3M0 →
DDX20	Probable ATP-dependent RNA helicase DDX20	0.982	landscape →
Q2KI79	—	0.982	Q2KI79 →
Q6ZQM0	—	0.982	Q6ZQM0 →
Q9H706	—	0.981	Q9H706 →
Q7TP65	—	0.981	Q7TP65 →
Q5SXH7	—	0.981	Q5SXH7 →
P56951	—	0.981	P56951 →
Q3US16	—	0.981	Q3US16 →
Q6NRE4	—	0.981	Q6NRE4 →
Q8C0R0	—	0.981	Q8C0R0 →
F1N5V1	—	0.981	F1N5V1 →
Q501R9	—	0.980	Q501R9 →
P79457	—	0.980	P79457 →
Q562E2	—	0.980	Q562E2 →
E1BPH3	—	0.980	E1BPH3 →
Q9D494	—	0.980	Q9D494 →
A2T737	—	0.980	A2T737 →
Q8NAT2	—	0.980	Q8NAT2 →
Q8WZ73	—	0.980	Q8WZ73 →
Q9DAU9	—	0.980	Q9DAU9 →
Q80VH0	—	0.980	Q80VH0 →
O14607	—	0.979	O14607 →
Q5F479	—	0.979	Q5F479 →
P97573	—	0.979	P97573 →
Q3UFT3	—	0.979	Q3UFT3 →
Q5SUS0	—	0.979	Q5SUS0 →
INPP5D	Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1	0.979	landscape →
F1SRY5	—	0.979	F1SRY5 →